Bibliographic Details
| Title: |
1653P Cabozantinib (C) vs placebo (P) in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who progressed after prior VEGFR-targeted therapy: Outcomes by duration of prior lenvatinib (L) treatment. |
| Authors: |
Brose, M.S.1 (AUTHOR), Krajewska, J.A.2 (AUTHOR), Vaisman, F.3 (AUTHOR), Hoff, A.O.4 (AUTHOR), Hitre, E.5 (AUTHOR), Oliver, J.6 (AUTHOR), Williamson, D.S.7 (AUTHOR), Berry, N.8 (AUTHOR), Capdevila Castillon, J.9 (AUTHOR) |
| Source: |
Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1297-S1298. 2p. |
| Database: |
Academic Search Ultimate |
